The focus on GBS is clearly cherry-picking one of the rarer and more transient adverse side effects, observed in a by now barely used vaccine, in order to take

The focus on GBS is clearly cherry-picking one of the rarer and more transient adverse side effects, observed in a by now barely used vaccine, in order to take up oxygen in the vaccine risks discussion and present the appearance of being on top of it. Says a lot that it is getting as much FDA attention as myocarditis, which is much more common (Israel estimated between 1 in 3000 and 1 in 6000 in men 16 to 24, far higher than the deceptive "few per million" presented in the article) and potentially more lasting.